Furui: Maintains "Buy" rating on Federal Pharmaceutical (03933.HK), raises target price to HK$20

According to the Wisdom Financial APP, Furui released a research report stating that considering that the intermediate and raw material pharmaceutical business of Federal Pharmaceutical (03933.HK) has expanded to 80 regions globally, in response to the latest revenue forecast for intermediates and raw materials. And the impact of milestone payments from Novo Nordisk, maintaining a "buy" rating, with a target price raised from HK$17 to HK$20.